Rabasa-Lhoret R, Rasamisoa M, Avignon A, Monnier L
Service des Maladies Métaboliques, Hôpital Lapeyronie, Centre Hospitalier Universitaire de Montpellier, 34295 Montpellier Cedex 05.
Diabetes Metab. 2001 Feb;27(1):66-8.
Fibrates are widely prescribed as hypolipidemic drugs and are considered as safe. We report the case of a 69 year-old woman who probably developed a major allergic reaction following a Fenofibrate prescription (generic form) of 300 mg per day. Clinical features included asthenia, hyperthermia (40.5 degrees C) and slight muscular pain. Biological abnormalities were mildly elevated muscular enzymes and pancytopenia rapidly developed. All bacteriologic, virologic, immune and radiologic investigations were normal. Evolution was spontaneously favorable with Fenofibrate withdrawal. This is the first reported case of major fever and pancytopenia following a Fenofibrate prescription. Adverse effects of Fenofibrate are briefly reviewed and their usual favorable outcomes following drug removal are outlined.
